In the first part of this interview, Gupta discussed the basics of GIST, and now he breaks down his advice for newly ...

GISTs are a rare type of cancer that develops in the digestive tract’s connective tissue, specifically from cells that help regulate muscle contractions. GISTs are primarily driven by genetic ...

Research is underway for an experimental treatment for patients with succinate dehydrogenase (SDH) deficient gastrointestinal ...

NEW YORK, March 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced breakthrough preclinical findings demonstrating the ...

The optimal duration of adjuvant imatinib has yet to be determined, and clinical trials are ongoing to address this. KIT-directed tyrosine kinase inhibitors (TKIs) are the key treatment for advanced ...

Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: ...

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient ...

Within the tumor microenvironment, networks of cells and molecular signals form a dynamic landscape that drives disease ...

Lantern Pharma (LTRN) announced additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 as well as ...